BR112013020454A2 - método de diagnóstico de câncer e kit para diagnóstico usando medição de atividade de célula nk - Google Patents

método de diagnóstico de câncer e kit para diagnóstico usando medição de atividade de célula nk

Info

Publication number
BR112013020454A2
BR112013020454A2 BR112013020454A BR112013020454A BR112013020454A2 BR 112013020454 A2 BR112013020454 A2 BR 112013020454A2 BR 112013020454 A BR112013020454 A BR 112013020454A BR 112013020454 A BR112013020454 A BR 112013020454A BR 112013020454 A2 BR112013020454 A2 BR 112013020454A2
Authority
BR
Brazil
Prior art keywords
diagnosis
kit
diagnostic method
cell activity
activity measurement
Prior art date
Application number
BR112013020454A
Other languages
English (en)
Other versions
BR112013020454B1 (pt
BR112013020454A8 (pt
Inventor
Jae Myun Lee
Jong Sun Kim
Joo Chun Yoon
Sang Woo Park
Original Assignee
Atgen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atgen Co Ltd filed Critical Atgen Co Ltd
Publication of BR112013020454A2 publication Critical patent/BR112013020454A2/pt
Publication of BR112013020454A8 publication Critical patent/BR112013020454A8/pt
Publication of BR112013020454B1 publication Critical patent/BR112013020454B1/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BR112013020454-0A 2011-02-14 2012-02-10 Método para medir a atividade de células assassinas naturais nk, proteína de fusão, composição para ativar células nk, kit para medir a atividade de célula nk BR112013020454B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020110012983A KR20120093002A (ko) 2011-02-14 2011-02-14 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
KR10-2011-0012983 2011-02-14
PCT/IB2012/000259 WO2012110878A2 (en) 2011-02-14 2012-02-10 Method of diagnosing cancer and diagnosis kit using measurement of nk cell activity

Publications (3)

Publication Number Publication Date
BR112013020454A2 true BR112013020454A2 (pt) 2016-10-18
BR112013020454A8 BR112013020454A8 (pt) 2022-11-29
BR112013020454B1 BR112013020454B1 (pt) 2023-03-21

Family

ID=46672988

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013020454-0A BR112013020454B1 (pt) 2011-02-14 2012-02-10 Método para medir a atividade de células assassinas naturais nk, proteína de fusão, composição para ativar células nk, kit para medir a atividade de célula nk

Country Status (20)

Country Link
US (2) US11442069B2 (pt)
EP (1) EP2676139B1 (pt)
JP (5) JP6629497B2 (pt)
KR (3) KR20120093002A (pt)
CN (1) CN103370622B (pt)
AU (2) AU2012219184A1 (pt)
BR (1) BR112013020454B1 (pt)
CA (1) CA2826053C (pt)
CL (1) CL2013002361A1 (pt)
DK (1) DK2676139T3 (pt)
EA (1) EA038959B1 (pt)
ES (1) ES2797549T3 (pt)
IL (1) IL227952B (pt)
MX (1) MX361731B (pt)
MY (1) MY175351A (pt)
RU (1) RU2635194C2 (pt)
SG (1) SG192247A1 (pt)
TW (2) TWI681191B (pt)
UA (1) UA120697C2 (pt)
WO (1) WO2012110878A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120093002A (ko) 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
WO2015069187A1 (en) 2013-11-05 2015-05-14 Agency For Science, Technology And Research Bladder Carcinoma Biomarkers
JP6073417B2 (ja) * 2015-06-26 2017-02-01 チャ バイオテック カンパニー リミテッド 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
KR101926166B1 (ko) * 2016-05-24 2018-12-06 재단법인 아산사회복지재단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
WO2017204446A2 (ko) * 2016-05-24 2017-11-30 울산대학교 산학협력단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
CN107686828A (zh) * 2016-08-04 2018-02-13 英普乐孚生物技术(上海)有限公司 一种nk细胞无血清培养基
CN106222140A (zh) * 2016-08-04 2016-12-14 英普乐孚生物技术(上海)有限公司 一种nk细胞无血清培养基及其配制方法
CN106085958A (zh) * 2016-08-04 2016-11-09 英普乐孚生物技术(上海)有限公司 一种nk细胞的制备方法
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
KR102090698B1 (ko) * 2017-08-24 2020-04-23 연세대학교 산학협력단 암의 진단, 모니터링, 또는 예후 예측을 위해 생체 외 인터페론-감마의 양을 측정하는 방법
BR112020015512A2 (pt) 2018-02-01 2021-01-26 Nkmax Co., Ltd. método de produção de células exterminadoras naturais e composição para tratamento de câncer
EP3924368A4 (en) * 2019-02-14 2022-12-14 Research Institute at Nationwide Children's Hospital USE OF A STIMULATING AGENT TO ANALYZE THE POWER OF IMMUNE CELLS
US20220288121A1 (en) * 2019-08-29 2022-09-15 Board Of Regents, The University Of Texas System Cell cryopreservation medium
US20230002731A1 (en) * 2019-11-29 2023-01-05 Nkmax Co., Ltd. Method of producing natural killer cells and compositions thereof
CN113533729B (zh) * 2021-06-15 2024-09-06 北京大学人民医院 一种鉴定aml患者骨髓中nk细胞耗竭的研究方法及其应用
EP4448554A1 (en) * 2021-12-17 2024-10-23 University of Kent Sequences and methods for production of recombinant biological molecules in vesicles
KR20230156518A (ko) 2022-05-06 2023-11-14 (주)다이오진 엑소좀 내의 인터페론 감마 유전자 측정을 이용한 암 조기 진단 방법 및 진단 키트
CN115247149B (zh) * 2022-08-22 2023-06-16 华域生物科技(天津)有限公司 适用于nk细胞的培养基组合物及培养方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2635088A (en) 1987-12-04 1989-06-08 Du Pont Merck Pharmaceutical Company, The Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension
CA2168584C (en) * 1993-08-09 2008-10-14 Edward Baral A method for sensitization of cancer cells for killer cell mediated lysis
AU695129B2 (en) * 1995-02-06 1998-08-06 Genetics Institute, Llc Formulations for IL-12
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
JP3995248B2 (ja) 2001-08-13 2007-10-24 準二郎 土山 エプスタインバーウイルス陰性のｎｋ細胞株
EP1451217A4 (en) * 2001-11-20 2005-10-12 Atgen Co Ltd NEW PEPTIDES PROVIDING ENVIRONMENTAL RESISTANCE, AND FUSION PROTEINS CONTAINING THOSE PEPTIDES
WO2003082206A2 (en) * 2002-03-26 2003-10-09 Centocor, Inc. Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses
JP2004305095A (ja) 2003-04-07 2004-11-04 Limuloid Science Kk 細胞活性化検出方法
CN1297567C (zh) * 2003-06-13 2007-01-31 马菁 具有抗肿瘤功能的双功能融合蛋白及其制备方法和应用
EP1925626A1 (en) * 2003-07-21 2008-05-28 Transgene S.A. Novel multifunctional cytokines
WO2005013950A2 (en) 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
AU2004288231A1 (en) 2003-11-05 2005-05-19 Palingen, Inc. Enhanced B cell cytotoxicity of CDIM binding antibody
KR100565764B1 (ko) 2005-05-02 2006-03-28 (주)에이티젠 환경 스트레스에 내성을 부여하는 신규한 펩타이드 및 이를포함하는 융합 단백질
US20050203010A1 (en) * 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
JP4653465B2 (ja) 2004-10-25 2011-03-16 泰信 小林 ナチュラルキラー細胞の増殖促進方法およびそれに用いる培養組成物
CA2604007A1 (en) * 2005-04-08 2006-10-19 Morningside Venture Investments Limited Use of fril proteins for reducing the production of pro-inflammatory cytokines
AU2007277050A1 (en) * 2006-07-28 2008-01-31 The Research Foundation Of State University Of New York Methods and kits for measurement of lymphocyte function
WO2008070647A1 (en) * 2006-12-07 2008-06-12 Wyeth Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample
ES2627923T3 (es) 2007-01-11 2017-08-01 Novo Nordisk A/S Anticuerpos anti-KIR, formulaciones y usos de los mismos
EP2048237A1 (en) * 2007-10-05 2009-04-15 Avir Green Hills Biotechnology Research Development Trade Ag Replication deficient Influenza virus for the expression of heterologous sequences
KR20120093002A (ko) 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트

Also Published As

Publication number Publication date
IL227952A0 (en) 2013-09-30
JP2022043119A (ja) 2022-03-15
KR20130136012A (ko) 2013-12-11
AU2012219184A1 (en) 2013-09-05
JP2019207242A (ja) 2019-12-05
TW201245718A (en) 2012-11-16
NZ614345A (en) 2015-09-25
RU2013141487A (ru) 2015-03-27
KR101341538B1 (ko) 2013-12-18
TWI668445B (zh) 2019-08-11
CL2013002361A1 (es) 2014-06-27
AU2017202628A1 (en) 2017-05-11
ES2797549T3 (es) 2020-12-02
TW201741670A (zh) 2017-12-01
MY175351A (en) 2020-06-22
KR101438573B1 (ko) 2014-09-12
UA120697C2 (uk) 2020-01-27
CN103370622A (zh) 2013-10-23
BR112013020454B1 (pt) 2023-03-21
MX2013009380A (es) 2013-12-16
JP2017129597A (ja) 2017-07-27
AU2017202628B2 (en) 2019-08-22
TWI681191B (zh) 2020-01-01
US20140017713A1 (en) 2014-01-16
EA201391187A1 (ru) 2013-12-30
RU2635194C2 (ru) 2017-11-09
JP6629497B2 (ja) 2020-01-15
KR20130032410A (ko) 2013-04-01
MX361731B (es) 2018-12-14
JP2023115006A (ja) 2023-08-18
CA2826053A1 (en) 2012-08-23
SG192247A1 (en) 2013-09-30
BR112013020454A8 (pt) 2022-11-29
US20220229070A1 (en) 2022-07-21
DK2676139T3 (da) 2020-06-15
EP2676139A4 (en) 2014-12-03
EP2676139A2 (en) 2013-12-25
IL227952B (en) 2019-01-31
JP2014510517A (ja) 2014-05-01
CN103370622B (zh) 2018-02-13
WO2012110878A3 (en) 2013-01-31
WO2012110878A2 (en) 2012-08-23
EP2676139B1 (en) 2020-05-06
NZ710432A (en) 2017-04-28
US11442069B2 (en) 2022-09-13
KR20120093002A (ko) 2012-08-22
CA2826053C (en) 2021-05-25
JP6798922B2 (ja) 2020-12-09
EA038959B1 (ru) 2021-11-15

Similar Documents

Publication Publication Date Title
BR112013020454A2 (pt) método de diagnóstico de câncer e kit para diagnóstico usando medição de atividade de célula nk
EP2758933A4 (en) CLINICAL ANALYSIS USING ELECTRODERMIC ACTIVITY
EP2712299A4 (en) METHODS AND ARRANGEMENTS FOR OBTAINING INFORMATION AND PROVIDING ANALYSIS FOR BIOLOGICAL TISSUES
BR112014007789A2 (pt) sistemas e métodos para análise biológica
HK1204377A1 (en) Methods for analyzing massively parallel sequencing data for noninvasive prenatal diagnosis
BR112013031019A2 (pt) teste diagnóstico molecular para câncer
EP2748631A4 (en) ULTRASOUND INSPECTION MATRIX
EP2737315A4 (en) CARTRIDGE FOR DIAGNOSTIC TESTS
BR112013000372A2 (pt) conjunto de ejeção de fluído e método para circular fluído
EP2931133A4 (en) ULTRASONIC TERMINAL CAP AND METHOD FOR TESTING AN ULTRASONIC SOUND AND ULTRASOUND DIAGNOSTIC SYSTEM THEREFOR
EP2788925A4 (en) SYSTEM AND METHOD FOR EVALUATING AND MARKETING CLINICAL RESEARCH CENTERS
HK1214360A1 (zh) 用於電化學分析的檢測裝置
DE102011078357A8 (de) Vorrichtung für eine Röntgenstrahlanalyse mit klassifizierten Wellenlängen
BR112013019162A2 (pt) método de análise e dispositivo de leitura de microarranjo
EP2733490A4 (en) BIFUNCTIONAL TUMOR DIAGNOSIS REAGENT AND METHOD THEREFOR
PL2844762T3 (pl) Badanie wrażliwości na antybiotyki przy użyciu sond do pre-rybosomalnego RNA
EP2825673A4 (en) METHOD, KIT AND CHIP FOR BIOMARKER VALIDATION AND CLINICAL USE
EP2719334A4 (en) ULTRASONIC DIAGNOSIS DEVICE AND ULTRASONIC MEASURING PROCESS THEREWITH
EP2716233A4 (en) ULTRASONIC SENSOR, DEVICE FOR MEASURING BIOLOGICAL INFORMATION AND METHOD FOR MEASURING BIOLOGICAL INFORMATION
SG11201401911XA (en) Systems and methods for biological analysis
IL232642A0 (en) A method for characterizing circulating cells and its use in diagnosis
SG11201404524WA (en) Methods for identifying agents with desired biological activity
BR112013028592A2 (pt) conjunto de sonda ultrassônica pivotante e métodos para seu uso
HK1192283A1 (zh) 用於膀胱癌診斷的序列及其使用方法和應用
IT1397674B1 (it) Procedimento ed apparecchiatura per analisi diagnostiche

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: NKMAX CO., LTD. (KR)

B25G Requested change of headquarter approved

Owner name: NKMAX CO., LTD. (KR)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/02/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.